170 CHAPTER 6 REFERENCES 1. Integraal Kankercentrum Nederland. Rapport “Uitgezaaide kanker in beeld”. 2020. 2. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;144(5):646-674. (In English). DOI: 10.1016/j.cell.2011.02.013. 3. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1(4):309-315. (In English). DOI: 10.1038/nrd773. 4. Roskoski R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 2015;100:1-23. (In English). DOI: 10.1016/j.phrs.2015.07.010. 5. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21(2):309-318. (In English). DOI: Doi 10.1016/S0149-2918(00)88288-0. 6. Olivier T, Haslam A, Prasad V. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. Jama Netw Open 2021;4(12) (In English). DOI: ARTN e2138793 10.1001/jamanetworkopen.2021.38793. 7. Santucci C, Carioli G, Bertuccio P, et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev 2020;29(5):367-381. (In English). DOI: 10.1097/Cej.0000000000000594. 8. Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 2019;575(7781):210-+. (In English). DOI: 10.1038/s41586-019-1689-y. 9. Garcia VM, Olmos D, Gomez-Roca C, et al. Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research 2014;20(22):5663-5671. (In English). DOI: 10.1158/1078-0432.Ccr-14-0719. 10. van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol 2019. DOI: 10.1093/annonc/mdz119. 11. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16(13):1324-1334. (In English). DOI: 10.1016/S1470-2045(15)00188-6. 12. Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine 2019;25(5):751-+. (In English). DOI: 10.1038/s41591019-0424-4. 13. Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine 2019;25(5):744-+. (In English). DOI: 10.1038/s41591-019-0407-5. 14. Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology 2020;38(33) (In English). DOI: 10.1200/Jco.19.03010.
RkJQdWJsaXNoZXIy MTk4NDMw